Extensive-Stage Small Cell Lung Cancer
ZLABZai LabCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Zocilurtatug pelitecan (formerly ZL-1310) in Extensive-Stage Small Cell Lung Cancer. The expected timing is based on the latest available company guidance and may change.
6/2/25- Presented data at ASCO'25. Initiate pivotal trial in 2L SCLC with selected optimal dose later this 2025. 10/24/25– Presented updated data at AACR-NCI-EORTC’25. 02/26/26:- 1L ES-SCLC Ph1 combo data in H2 2026; plan registrational study 2026. 03/17/26:- AACR Apr 21, 2026 poster shows intracranial activity in ES-SCLC brain mets. H2 2026 combo data expected. 04/17/26:- Ph1 intracranial iORR 53.7% in ES-SCLC brain mets; safety manageable. AACR 2026 presentation planned. 05/07/26:- AACR2026 ES-SCLC brain mets: iORR 53.7%, 62.5% at 1.6 mg/kg; manageable safety; H2 2026 combo Ph1 data. 05/11/26:- Fast Track designation in ES-SCLC reiterated; registrational studies across 1L, 2L, epNEC planned by end 2026. 06/16/26:- EMA Orphan Drug Designation for pulmonary NECs; COMP cited durable responses in relapsed/refractory ES-SCLC. 08/06/26:- ESMO 2026 Ph1 combo data; registrational Ph3 planned H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.